Wandercraft Raises $75M Series D : Acceleration of AI-Powered Robotics at Global Scale

Laurent Van Lerberghe
4 hours ago
3 min read

On June 11, 2025, Wandercraft a pioneering French robotics company announced the successful close of its Series D funding round. raising $75 million in equity and debt financing. This capital injection comes at a pivotal moment for the company, as it prepares to scale its robotics solutions across healthcare, personal mobility, and industrial sectors.

Backed by a consortium of strategic and institutional investors including Renault Group, the PSIM fund (managed by Bpifrance under France 2030), Teampact Ventures and Quadrant Management, among others, the round reflects strong confidence in Wandercraft’s mission and long-term vision.

From rehabilitation to Real-World mobility and industry a robotics company scaling up

With the newly secured funding, Wandercraft is accelerating its expansion into two complementary domains:

Personal mobility for daily life: The company aims to launch Eve the world’s first self-balancing personal exoskeleton by 2026. Eve is designed to restore independence to individuals relying on wheelchairs, enabling them to stand, walk, and navigate daily environments without crutches or walkers.
Industrial robotics and humanoid automation: Wandercraft is also developing a new line of autonomous humanoid robots, starting with Calvin-40 designed for physically demanding tasks in factory settings. The strategic partnership with Renault Group now a minority shareholder and first commercial client aims to leverage industrial-scale manufacturing and facilitate large-scale deployment of these robots on production floors.

As the company states, the moment is “extraordinary,” fueled by global expansion, active clinical trials, and an intensifying push for commercialization and industrialization.

Why this matters : Health, Inclusion & Industry Convergence

For healthcare and society

Wandercraft’s trajectory directly addresses deep societal challenges: mobility, disability, aging populations, and quality-of-life. By deploying Atalante X in clinics and preparing Eve for home and community use, Wandercraft is building bridges between rehabilitation and autonomous living potentially restoring independence to individuals who’ve long relied on wheelchairs or assistance.

For industry and automation

With Calvin-40 and future humanoids, Wandercraft is entering the industrial automation arena not as a typical automation vendor, but with AI-powered, bipedal robots capable of tasks that historically depended on humans or cumbersome machinery. The collaboration with Renault Group — a major industrial and automotive player is a strong indicator of ambition, capacity, and credibility.

For investors and markets

This Series D round crystallizes a clear growth inflection point: from a deep-tech rehabilitation start-up to a multi-domain robotics player. The diversified roadmap medical devices, personal mobility, industrial automation represents multiple, complementary addressable markets. The backing by a mix of strategic investors, sovereign-linked funds (via Bpifrance), and industry heavyweights suggests both social impact and real commercial scalability.

What to watch : Key milestones ahead

2026 : Target launch of Eve: first personal exoskeleton for daily life mobility.
Scaling Atalante X : Broader clinical adoption globally, expanding rehabilitation access.
Industrial rollout of Calvin-40 (and future humanoids) : First factory deployments, with potential to transform labor-intensive or ergonomically difficult tasks.
Global footprint expansion : From Europe and U.S. rehabilitation markets to homes worldwide, industrial clients, and supply-chain integrations.

Why we at ballas invest are confident and committed

At ballas invest, our mission is to support companies that combine technological excellence, data-driven innovation, and societal impact. Wandercraft embodies that mission. Their bold vision giving walking autonomy to those who have lost it, and redefining robotics not just for factories, but for human mobility is both deeply meaningful and potentially market-disruptive.

This $75 M Series D isn’t just a financing round: it’s a launch pad. For Wandercraft, for the robotics sector, and for all stakeholders invested in inclusive, AI-driven healthcare and industry. We are proud to stand alongside them on this journey.

Man smiling in a street wearing an exoskeleton labeled Wandercraft. Background shows a café, plants, and chairs. Mood is cheerful.